KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Assets (2016 - 2026)

Idexx Laboratories has reported Assets over the past 17 years, most recently at $3.4 billion for Q4 2025.

  • For Q4 2025, Assets rose 1.74% year-over-year to $3.4 billion; the TTM value through Dec 2025 reached $3.4 billion, up 1.74%, while the annual FY2025 figure was $3.4 billion, 1.74% up from the prior year.
  • Assets for Q4 2025 was $3.4 billion at Idexx Laboratories, down from $3.4 billion in the prior quarter.
  • Over five years, Assets peaked at $3.4 billion in Q2 2024 and troughed at $2.3 billion in Q1 2021.
  • A 5-year average of $2.9 billion and a median of $3.0 billion in 2023 define the central range for Assets.
  • Biggest five-year swings in Assets: increased 23.39% in 2021 and later decreased 4.17% in 2025.
  • Year by year, Assets stood at $2.4 billion in 2021, then increased by 12.7% to $2.7 billion in 2022, then increased by 18.68% to $3.3 billion in 2023, then grew by 1.03% to $3.3 billion in 2024, then grew by 1.74% to $3.4 billion in 2025.
  • Business Quant data shows Assets for IDXX at $3.4 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.3 billion in Q2 2025.